Replies to post #27535 on Intellipharmaceutics International Inc. (IPCI)

[Tekterra]

I agree to some degree. That's why we won't see a big jump on the stock price. But, it should trend up over time.

The Purdue case is that IPCI is counter suing. Typically, you don't counter sue unless you have some solid chance to win. Represented by good lawyers, and looking at other cases in the past, IPCI should come out on top eventually. That means they save the expense from the law suit.

The question is how soon? Also, will FDA still move forward regardless of the case and grant a tentative approval remains to be seen.

[doogdilinger]

Not that hard to do ones due on how much potential revenue this deal will result in...especially when IPCI themselves have been projecting that as long as SeroquelXR launches full commercialization by their fiscal Q3 they expect to attain cash flow positive status. But here's a recap of Mackie analysts projected SeroquelXR revenues...and a copy/paste beneath it from the last paragraph of todays PR which gives great insights on SeroquelXR's market>>>

According to Symphony Health Solution, sales in the U.S. for 12 month ended August 2015 for brand Seroquel XR were approx.
US$1.2BN. We are assuming market size would decrease by 35% to US$780M per year after its genericization. We estimate IPCI’s
generic Seroquel XR would take max. 9% of the market and after that the market share would drop by 20% on yearly basis. We are
assuming a gross margin of 80% and that IPCI and Mallinckrodt would evenly split the gross profit. Our estimates of IPCI’s share
from its generic Seroquel XR sales in the U.S. from 2017 to 2020 are US$13.5M, US$21.2M, US$17.0M, and US$13.6M, respectively.

Seroquel XR®, and the drug active quetiapine fumarate, are indicated for use in the treatment of schizophrenia and bipolar disorder. According to Symphony Health Solutions, sales in the United States for the 12 months ended April 2017 of the 50, 150, 200, 300 and 400 mg strengths of Seroquel XR® (branded and generic) were approximately U.S. $842 million (TRx MBS Dollars, which represents projected new and refilled prescriptions representing a standardized dollar metric based on manufacturer's published catalog or list prices to wholesalers, and does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price).  There can be no assurance that the Company's generic Seroquel XR® in any of the 50, 150, 200, 300 and 400 mg strengths will be successfully commercialized.